Blinded analyses were aimed to determine how different atypical Positive and Negative Syndrome Scale (PANSS) score profiles (identified using algorithms) were able to predict early termination.
About the Author
Dr. Mark Opler serves as Chief Research Officer, directing scientific research and development at MedAvante-ProPhase. Dr. Opler was the founder of ProPhase and served as its CEO and Chief Scientific Officer among other positions. He holds the titles of Adjunct Assistant Professor of Psychiatry at New York University and Assistant Professor of Clinical Neuroscience at Columbia University’s College of Physicians and Surgeons. His academic research focuses on the etiology, phenomenology, and treatment of serious and persistent mental disorders. He is also leading the development of the new upcoming edition of the PANSS Manual©.
Follow on Linkedin
More Content by Dr. Mark Opler, PhD, MPH | Chief Research Officer
